|
1
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lai EC: MicroRNAs are complementary to 3′
UTR sequence motifs that mediate negative post-transcriptional
regulation. Nat Genet. 30:363–364. 2002.
|
|
3
|
Berezikov E, Guryev V, van de Belt J,
Wienholds E, Plasterk RH and Cuppen E: Phylogenetic shadowing and
computational identification of human microRNA genes. Cell.
120:21–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha
V, Lindblad-Toh K, Lander ES and Kellis M: Systematic discovery of
regulatory motifs in human promoters and 3′ UTRs by comparison of
several mammals. Nature. 434:338–345. 2005.
|
|
5
|
Shi XB, Tepper CG and deVere White RW:
Cancerous miRNAs and their regulation. Cell Cycle. 7:1529–1538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mezzanzanica D, Bagnoli M, De Cecco L,
Valeri B and Canevari S: Role of microRNAs in ovarian cancer
pathogenesis and potential clinical implications. Int J Biochem
Cell Biol. 42:1262–1272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Gong J, Zeng H, et al: MicroRNA145
targets BNIP3 and suppresses prostate cancer progression. Cancer
Res. 70:2728–2738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong Q, Meng P, Wang T, et al: MicroRNA
let-7a inhibits proliferation of human prostate cancer cells in
vitro and in vivo by targeting E2F2 and CCND2. PLoS One.
5:e101472010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Patchell RA: The management of brain
metastases. Cancer Treat Rev. 29:533–540. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nathoo N, Chahlavi A, Barnett GH and Toms
SA: Pathobiology of brain metastases. J Clin Pathol. 58:237–242.
2005. View Article : Google Scholar
|
|
13
|
Schouten LJ, Rutten J, Huveneers HA and
Twijnstra A: Incidence of brain metastases in a cohort of patients
with carcinoma of the breast, colon, kidney, and lung and melanoma.
Cancer. 94:2698–2705. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smedby KE, Brandt L, Bäcklund ML and
Blomqvist P: Brain metastases admissions in Sweden between 1987 and
2006. Br J Cancer. 101:1919–1924. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Penel N, Brichet A, Prevost B, Duhamel A,
Assaker R, Dubois F and Lafitte JJ: Pronostic factors of
synchronous brain metastases from lung cancer. Lung Cancer.
33:143–154. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Steeg PS: Tumor metastasis: mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Braun S, Vogl FD, Naume B, et al: A pooled
analysis of bone marrow micrometastasis in breast cancer. N Engl J
Med. 353:793–802. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roodman GD: Mechanisms of bone metastasis.
Discov Med. 4:144–148. 2004.
|
|
20
|
Fidler IJ: Modulation of the organ
microenvironment for treatment of cancer metastasis. J Natl Cancer
Inst. 87:1588–1592. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Radinsky R: Molecular mechanisms for
organ-specific colon carcinoma metastasis. Eur J Cancer.
31:1091–1095. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Radinsky R and Ellis LM: Molecular
determinants in the biology of liver metastasis. Surg Oncol Clin N
Am. 5:215–229. 1996.PubMed/NCBI
|
|
23
|
Fitzgerald DP, Palmieri D, Hua E, Hargrave
E, Herring JM, Qian Y, Vega-Valle E, Weil RJ, Stark AM, Vortmeyer
AO and Steeg PS: Reactive glia are recruited by highly
proliferative brain metastases of breast cancer and promote tumor
cell colonization. Clin Exp Metastasis. 25:799–810. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dykxhoorn DM, Wu Y, Xie H, et al: miR-200
enhances mouse breast cancer cell colonization to form distant
metastases. PLoS One. 4:e71812009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Ach RA and Curry B: Direct and
sensitive miRNA profiling from low-input total RNA. RNA.
13:151–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He TC, Zhou S, da Costa LT, et al: A
simplified system for generating recombinant adenoviruses. Proc
Natl Acad Sci USA. 95:2509–2514. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lima RT, Busacca S, Almeida GM, Gaudino G,
Fennell DA and Vasconcelos MH: MicroRNA regulation of core
apoptosis pathways in cancer. Eur J Cancer. 47:163–174. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Varnholt H, Drebber U, Schulze F,
Wedemeyer I, Schirmacher P, Dienes HP and Odenthal M: MicroRNA gene
expression profile of hepatitis C virus-associated hepatocellular
carcinoma. Hepatology. 47:1223–1232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu X, Sempere LF, Galimberti F, et al:
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer
Res. 15:1177–1183. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dyrskjøt L, Ostenfeld MS, Bramsen JB, et
al: Genomic profiling of microRNAs in bladder cancer: miR-129 is
associated with poor outcome and promotes cell death in vitro.
Cancer Res. 69:4851–4860. 2009.PubMed/NCBI
|
|
31
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arndt GM, Dossey L, Cullen LM, et al:
Characterization of global microRNA expression reveals oncogenic
potential of miR-145 in metastatic colorectal cancer. BMC Cancer.
9:3742009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Götte M, Mohr C, Koo CY, et al:
miR-145-dependent targeting of junctional adhesion molecule A and
modulation of fascin expression are associated with reduced breast
cancer cell motility and invasiveness. Oncogene. 29:6569–6580.
2010.PubMed/NCBI
|
|
34
|
Wu BL, Xu LY, Du ZP, et al: MiRNA profile
in esophageal squamous cell carcinoma: downregulation of miR-143
and miR-145. World J Gastroenterol. 17:79–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fuse M, Nohata N, Kojima S, et al:
Restoration of miR-145 expression suppresses cell
proliferation, migration and invasion in prostate cancer by
targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.
|
|
37
|
Peng X, Guo W, Liu T, et al:
Identification of miRs-143 and -145 that is associated with bone
metastasis of prostate cancer and involved in the regulation of
EMT. PLoS One. 6:e203412011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kano M, Seki N, Kikkawa N, et al:
miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar
|
|
39
|
Akagi I, Miyashita M, Ishibashi O, et al:
Relationship between altered expression levels of MIR21, MIR143,
MIR145, and MIR205 and clinicopathologic features of
esophageal squamous cell carcinoma. Dis Esophagus. 24:523–530.
2011.
|
|
40
|
Chiyomaru T, Enokida H, Tatarano S, et al:
miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar
|
|
41
|
Cho WC, Chow AS and Au JS: Restoration of
tumour suppressor hsa-miR-145 inhibits cancer cell growth in
lung adenocarcinoma patients with epidermal growth factor receptor
mutation. Eur J Cancer. 45:2197–2206. 2009.PubMed/NCBI
|
|
42
|
Cho WC, Chow AS and Au JS: MiR-145
inhibits cell proliferation of human lung adenocarcinoma by
targeting EGFR and NUDT1. RNA Biol. 8:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fidler IJ: Seed and soil revisited:
contribution of the organ microenvironment to cancer metastasis.
Surg Oncol Clin N Am. 10:257–269. 2001.PubMed/NCBI
|
|
44
|
Radinsky R: Modulation of tumor cell gene
expression and phenotype by the organ-specific metastatic
environment. Cancer Metastasis Rev. 14:323–338. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gupta GP and Massagué J: Cancer
metastasis: building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Poste G and Fidler IJ: The pathogenesis of
cancer metastasis. Nature. 283:139–146. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fidler IJ: The organ microenvironment and
cancer metastasis. Differentiation. 70:498–505. 2002. View Article : Google Scholar : PubMed/NCBI
|
